KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBT: 2009-2024

Historic EBT for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$119.2 million.

  • Nektar Therapeutics' EBT rose 5.47% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.8 million, marking a year-over-year increase of 32.38%. This contributed to the annual value of -$119.2 million for FY2024, which is 56.84% up from last year.
  • Per Nektar Therapeutics' latest filing, its EBT stood at -$119.2 million for FY2024, which was up 56.84% from -$276.3 million recorded in FY2023.
  • Nektar Therapeutics' 5-year EBT high stood at -$119.2 million for FY2024, and its period low was -$524.4 million during FY2021.
  • For the 3-year period, Nektar Therapeutics' EBT averaged around -$255.8 million, with its median value being -$276.3 million (2023).
  • Its EBT has fluctuated over the past 5 years, first fell by 18.13% in 2021, then skyrocketed by 56.84% in 2024.
  • Over the past 5 years, Nektar Therapeutics' EBT (Yearly) stood at -$443.9 million in 2020, then declined by 18.13% to -$524.4 million in 2021, then rose by 29.09% to -$371.9 million in 2022, then increased by 25.72% to -$276.3 million in 2023, then surged by 56.84% to -$119.2 million in 2024.